PTO/SB/01A (09-04)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN **APPLICATION DATA SHEET (37 CFR 1.76)**

Title of Invention	Method for Early Detection of Ovarian Cancer	
As the below named inventor(s), we declare that:		
This declaration is directed to:		
	The attached application, or	
	x Application No. <u>10/595,135</u> , filed on <u>March 2, 2006</u> ,	
	as amended on (If applicable);	
we believe that we am are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;		
we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;		
we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the continuation-in-part application.		
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.		
Power of Attorney We appoint the practitioners at customer number 57381, and Marina Larson, registration number 32,038 as our attorneys to prosecute this application.		
FULL NAME (DF INVENTOR(S)	
Inventor one: David Spriggs		
Signature:	Citizen of: US	
Inventor two: Jakob Dupont		
Signature:	Citizen of: US	
Inventor three:		
Signature:	Citizen of:	
Inventor four:		
Signature:	Citizen of:	
Addition	al inventors or legal representative are being named on additional form(s) attached hereto.	

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. ime will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	Method for Early Detection of Ovarian Cancer	
As the below named inventor(s), we declare that:		
This declaration	on is directed to:	
	The attached application, or	
	x Application No. <u>10/595,135</u> , filed on <u>March 2, 2006</u> ,	
	as amended on (If applicable);	
we believe that sought;	at we am are the original and first inventor(s) of the subject matter which is claimed and for which a patent is	
	ewed and understand the contents of the above-identified application, including the claims, as amended by any pecifically referred to above;	
to patentability	ge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available ling date of the prior application and the national or PCT International filing date of the continuation-in-part application.	
true, and furth	s made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be ter that these statements were made with the knowledge that willful false statements and the like are punishable by Inment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.	
Power of Atto We appoint the prosecute this	he practitioners at customer number 57381, and Marina Larson, registration number 32,038 as our attorneys to	
FULL NAME (OF INVENTOR(S)	
Inventor one:	David Spriggs	
_	Citizen of: US	
Inventor two:	Jakob Dupont	
Signature:	Citizen of: US	
Inventor three	:	
	Citizen of:	
Inventor four:		
	Citizen of:	
Addition	al inventors or legal representative are being named onadditional form(s) attached hereto.	

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1 63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. interval in a submitting the completed application form to the USPTO. interval in a submitting the complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.